CMN Weekly (9 May 2025) - Your Weekly CRISPR...
CMN Weekly
May. 9, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
mCureX Therapeutics
Main (gene editing) focus: Next-generation mRNA therapeutics
Company stage: Pre-clinical
Diseases: Genetic diseases, infectious diseases, cancer
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Website:https://www.mcurextx.com/en
Pipeline:https://www.mcurextx.com/en/rnd/pipeline
Location: Seongnam, Gyeonggi, South Korea
Partners: ToolGen
mCureX Therapeutics is a subsidiary of OliX Therapeutics. The company develops next-generation mRNA therapeutics and vaccines within different disease areas. In 2022, the company announced a collaboration with ToolGen to advance mRNA-based CRISPR-Cas9 gene editing to treat genetic eye diseases.
